Clinical Trial Update: Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing immunogenicity and safety of different vaccination schedules for a tetravalent dengue vaccine in healthy adults and adolescents; resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue Fever
• Dengue Hemorrhagic Fever

Drugs mentioned

• Tetravalent dengue vaccine

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Status: COMPLETED | Results posted: 2021-02-23